Background: Previous studies show that overexpression of EMMPRIN involved in the malignant biological behavior of tumors. This investigation was to disclose the expression status of EMMPRIN in non-small cell lung cancer (NSCLC) and its clinical value for the diagnosis of NSCLC.
Methods: The expression of EMMPRIN was examined using immunohistochemistry and enzyme-linked immunosorbent assay. The clinical value of EMMPRIN was evaluated by drawing a receiver operating characteristic (ROC) curve.
Results: NSCLC tissues and serum exhibited higher expression levels of EMMPRIN than the normal control (p < 0.05), and the expression of the EMMPRIN was significantly associated with lymphatic invasion and advanced stage of NSCLC (p < 0.05). ROC curve suggested that the threshold level of serum EMMPRIN for distinguishing NSCLC from control group was 80.3 pg/mL, and displayed a sensitivity of 97.22% and a specificity of 95%. And higher EMMPRIN expression in serum and tissues appeared to be risk factors for NSCLC development (risk ratio =1.56 and 1.1).
Conclusion: Overexpression of EMMPRIN was associated with lymphatic metastasis and advanced stage of NSCLC and test of serum EMMPRIN contributes to the NSCLC diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745773 | PMC |
| http://dx.doi.org/10.1186/s12890-017-0540-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting autophagy in HCC treatment: exploiting the CD147 internalization pathway.
Cell Commun Signal
December 2024
Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, 710032, China.
Background/aims: Chemotherapy resistance in liver cancer is a major clinical issue, with CD147 playing a vital role in this process. However, the specific mechanisms underlying these processes remain largely unknown. This study investigates how CD147 internalization leads to cytoprotective autophagy, contributing to chemotherapy resistance in hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFMonocarboxylate transporter dependent mechanism is involved in proliferation, migration, and invasion of human glioblastoma cell lines via activation of PI3K/Akt signaling pathway.
PLoS One
October 2024
Department of General Practice, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, China.
Glioblastoma multiforme is one of the most common primary tumors of the central nervous system, with a very poor prognosis. Cancer cells have been observed to upregulate pH regulators, such as monocarboxylate transporters (MCTs), with an increase in MCT4 expression being observed in several malignancies. MCT4/ recombinant cluster of differentiation 147 (CD147) transporter complex was reported to stimulate vascular endothelial growth factor (VEGF) via the phosphatidylinositol 3 kinase (PI3K) /protein kinase B (Akt) pathway, which has been proven to mediate glioblastoma invasion and migration.
View Article and Find Full Text PDFMetabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview.
Int J Mol Sci
August 2024
Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.
Article Synopsis
- - Hematological malignancies are diverse cancers of the blood and lymphatic system, including leukemias, lymphomas, and multiple myeloma, distinguished by their cell origins, genetic changes, and clinical features.
- - Metabolic adaptation and immune evasion play key roles in the survival and proliferation of these cancers, often leading to resistance against conventional therapies.
- - CD147 is a promising target for new treatments, as it influences cancer cell metabolism and interaction with key proteins, offering potential pathways for improved therapies in blood-related cancers.
The adhesin RadD enhances Fusobacterium nucleatum tumour colonization and colorectal carcinogenesis.
Nat Microbiol
September 2024
Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Article Synopsis
- Fusobacterium nucleatum can promote intestinal tumors by attaching to colorectal cancer (CRC) cells through a specific adhesin called RadD.
- RadD binds to CD147, a receptor found in higher amounts on CRC cells, triggering a signaling cascade that boosts tumor growth in mice.
- High levels of the radD gene in CRC tissue are linked to aggressive cancer behavior and worse patient outcomes, making the RadD-CD147 interaction a potential target for new CRC therapies.
Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers.
Cancer Immunol Immunother
July 2024
Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chimeric antigen receptor (CAR) T cell therapy has shown promising results in hematologic malignancies, but its effectiveness in solid cancers remains challenging. Macrophages are immune cells residing within the tumor microenvironment. They can phagocytose tumor cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!